Targeted Cancer Therapies
Sotorasib
BPT-1211 · Tablet
What is it used for?
Targets the KRAS G12C protein. Used for specified previously treated locally advanced or metastatic non-small-cell lung cancers with a confirmed KRAS G12C mutation; it does not apply to all lung cancers or all KRAS mutations.
- Dosage form
- Tablet
- Listed strengths
- 120 mg & 320 mg
- Listed pack size
- 56's & 90's
- Mechanism
- KRAS G12C inhibitor
Specifications supplied in the Everest product list; formulation, pack configuration, availability and local authorization require confirmation. These medicines are not for self-medication.
Clinical use overview
- Previously treated KRAS G12C non-small-cell lung cancer
Important information
Educational information about the active ingredient, not a treatment recommendation or a claim that Beptide's presentation is approved. Approved uses differ by country and product. Cancer medicines require specialist assessment; biomarkers, stage, previous treatments and combinations can determine eligibility.
FDA prescribing information
